Your SlideShare is downloading. ×
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
biocon &
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

biocon &


Published on

A neutral study on biocon & sme untold or unheard truths in last slide abt

A neutral study on biocon & sme untold or unheard truths in last slide abt

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 2.
    • India’s Leading Biotech enterprise
    • Established in 1978
    • Focus on development of Biopharmaceuticals
    • 1 st in Asia & 16 th in world in terms of revenue and market capitalization
    • Syngene, India’s first biotech custom research company in drug discovery
    • First company to manufacture human insulin using a Pichia expression system
    • India’s first billion dollar biotech company
  • 3. Products include: Biopharmaceuticals Anti-Diabetic Agents Anti-Hypertensive Agents Anti-Inflammatory Agents Antioxidants Cardiovascular Agents Digestive Aid Enzymes Haemostatic Agents Hepatoprotective Agents Immunosuppressants Nutraceuticals Enzymes Amylases Cellulases Esterases Glucanases Hemicellulases/Xylanases Oxidases Pectinases Proteases Tannase
  • 4.
    • Born on 23 March 1953 in Bangalore
    • B.Sc Zoology from Bangalore university 1973
    • Master brewer from Ballarat University in Melbourne 1975
    • Trainee brewer in Carlton & United Beverages in 1975-77
    • First Indian woman brew master
    • Joined Biocon biochemical Ltd. Ireland in 1978
    Dr. Kiran M. Shaw In 1978 founded Biocon India
  • 5. The journey begins…
    • Collaborated with irish firm Biocon international
    • Kiran owned 70% and Auchinloss (biocon int.) owned 30% of equity
    • Started Biocon India from her garage.
    • Initial Capital Rs/- 10,000.
    • Started extracting enzyme (papain) from papaya & isinglass (fish moss)
    • Export to irish firm
    • Novel product patenting
      • e.g: Enzyme to clarify tea
  • 6.
    • Early Hurdles:
    • Financing regular operations
    • Approached financial institutions, but turned down, coz:
        • Biotechnology is a new word
        • No assets for company
        • Woman entrepreneur is a rare word
    • Recruiting staff
        • Only well qualified people
    • In 1985,
        • Employees join communist labor union
        • Kiran automated the whole plant
  • 7.
    • Early years
    • Started with loan from KSFC
    • Proactive scientific interest
        • Building up germplasm of tropical m.o (Biodiversity)
        • Doing research on the metabolites of these m.o
    • Did not start antibiotic prod. (no commodity production in early stage)
    • HUMAN CAPITAL / PEOPLE (5 th P of marketing strategy)
        • Exceptionally well qualified individuals
        • Above average salary
        • Elegant & Refined working environment
        • Constant company of proff. (real good people with real good people)
        • Calling first names in company
        • Very much structured and purposive manner
        • ESOP
        • Attrition rate less than 1% (turnover only due to higher studies)
  • 8.
    • Breakthrough:
    • Switched from “uninspiring low technology” to high end technology
    • New technology replaced tray based conventional culture
    • Plafractor Bioreactor: all m.o processes in a computerized closed system
    • Acted as a technology bridge (platform technology)
    • Enabled biocon to cross from ind. Enzymes to biopharmaceuticals
    • Started R&D in immunosuppressants (reduce immune rejections)
  • 9.
    • Strategies
    • No commodity production in beginning due to lack of infrastructure
    • Diversification rather than expansion
    • Formed Helix (antibiotic prod.)
    • Formed Syngene, Clinigene (R&D in fermentation)
    • Biocon Quest (BQ) to produce these products in mass
    • Marketing strategy
    • Enzymes produced & sold as industrial intermediaries
    • Customer (staying with buyer’s processing line helping them obtain desired result from the enzyme)
    • Created an image of a reliable company able to give highly competent technical products & support
    • Also custom based products at any level
  • 11. 2004,Post IPO, became the richest Indian woman (U.S $ 480 million) I978, started Biocon India Ltd. in collaboration with Biocon Int. 1990s, Unilever collaboration & Plafractor technology 1998, Biocon became a separate identity by buying Unilever share. 1996, got into Biopharmaceuticals & statins
  • 12.
    • Noteworthy Decisions
    • Emphasizing on significant product & applications even when company is tiny
    • Contract R&D firm to outsource research
    • Systematic collection & cataloguing of tropical m.o for future (biodiversity pool)
    • ESOP for retaining employees
    • Launch of Insurgen , first branded formulation (Recombinant Human Insulin)
    • Managing IPR
    • Core emphasis right from the beginning
    • Major IP management came with invention of Plafractor
    • Joined PCT which gave a lot of protection and time to explore countries.
    • Got into Human insulin production by attaining a process patent
        • Produced Human Insulin through Pichia Yeast (biodiversity pool helped)
        • Mutual beneficial partnership with Nobex for oral insulin delivery
    • Determination
    • Willingness to take risk
    • Talented team
    • Spirit of Adventure
  • 14. Future
    • ORAL INSULIN has the potential to be India’s first proprietary
    • biotech blockbuster drug by 2010
        • • Pre-clinical studies to evaluate safety and efficacy in animal models has commenced.
        • • Biocon has initiated discussions with Pharma majors for licensing Oral Insulin for global markets.
    • ORAL PEPTIDE product for cardio vascular disease
        • Joined with U.S based Nobex Corp.
        • Plan to build Asia’s largest Antibody facility
        • Joined with CIMAB (renowned Cuban research Inst.)
        • Psoriasis
        • Rheumatoid Arthritis
        • 3 Cancer vaccines
  • 15.  
  • 16.  
  • 17. Brand
    • Dynamic Helix or Dynalix
    • Multiple associations like DNA helix, molecules, interlocking ‘B’s (Biocon & Biotech )
    • Slanting shows company’s forward and upward vision
    • About Branding:
        • To convey innovation , quality, reliability, distinctiveness & int. outlook
        • Pale blue packaging was chosen to stand out among std. white packages
  • 18. Recognition: Padma Bhushan (2005) The Economic Times Business Woman of the Year Award (2004) Ernst & Young Entrepreneur of the Year Award in Healthcare & Life Sciences (2002) Padma Shri (1989) Outstanding Young Person Award by Jaycees (1987) Rotary award for the Best Model Employer (1983) Outstanding Contribution Award (AWAKE) (1983) Gold for Best Woman Entrepreneur , Institute of Marketing Management (1982) Positions Held: Chairperson and Mission Leader of CII's National Task Force on Biotechnology Member, Board of Science Foundation, Ireland Member, Board of Governors, IIM Bangalore Chairperson, Karnataka's Vision Group on Biotechnology Vice-President, Association of Women Entrepreneurs of Karnataka (AWAKE)
  • 19. "If I can build a company like Biocon, anyone can… The first step was to dream however big or small…. If you have a vision, no matter how big or small, a plan, no matter if it is imperfect, but if there is passion and conviction for it, success is inevitable." - Kiran Mazumdar Shaw, Managing Director, Biocon India Limited.
  • 20.
    • Evil Face OF Ms. Shaw
    • Export of banned drug intermediate from china
    • Defaming Brand India by violating contracts
    • Started ABLE just for benefit of Biocon
    • Trying to monopolize biotech industry in india
  • 21. THANK YOU